SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

CORRESP Filing

DiaMedica Therapeutics Inc.
Date: Aug. 20, 2025 · CIK: 0001401040 · Accession: 0001437749-25-027408

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-289542

Date
August 20, 2025
Author
/s/ Rick Pauls
Form
CORRESP
Company
DiaMedica Therapeutics Inc.

Letter

dmtp20250819_corresp.htm

DIAMEDICA THERAPEUTICS, INC.

301 CARLSON PARKWAY, SUITE 210

MINNEAPOLIS, MN 55305 USA

T 763 496 5454

E INFO@DIAMEDICA.COM

W WWW.DIAMEDICA.COM

August 20, 2025

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, NE

Washington, DC 20549

Attention: Tyler Howes

Re:

DiaMedica Therapeutics Inc.

Registration Statement on Form S-3

Filed August 12, 2025

File No. 333-289542

Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 of the Securities Act of 1933, as amended, DiaMedica Therapeutics Inc. (the “Registrant”) hereby respectfully requests that the effective date of the above-referenced registration statement be accelerated so that it will be declared effective at 9:00 a.m., Eastern Time, on August 22, 2025, or as soon thereafter as is practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes Alston & Bird LLP, counsel to the Registrant, to orally modify or withdraw this request for acceleration.

The Registrant requests that it be notified of such effectiveness by a telephone call to Matthew Mamak of Alston & Bird LLP at (212) 210-1256.

Thank you for your assistance in this matter. Should you have any questions, please call Mr. Mamak.

Very truly yours,
/s/ Rick Pauls

Show Raw Text
CORRESP
 1
 filename1.htm

 dmtp20250819_corresp.htm

 DIAMEDICA THERAPEUTICS, INC.

 301 CARLSON PARKWAY, SUITE 210

 MINNEAPOLIS, MN 55305 USA

 T 763 496 5454

 E INFO@DIAMEDICA.COM

 W WWW.DIAMEDICA.COM

 August 20, 2025

 VIA EDGAR

 Securities and Exchange Commission

 Division of Corporation Finance

 Office of Life Sciences

 100 F Street, NE

 Washington, DC 20549

 Attention: Tyler Howes

 Re:

 DiaMedica Therapeutics Inc.

 Registration Statement on Form S-3

 Filed August 12, 2025

 File No. 333-289542

 Request for Acceleration

 Ladies and Gentlemen:

 Pursuant to Rule 461 of the Securities Act of 1933, as amended, DiaMedica Therapeutics Inc. (the “Registrant”) hereby respectfully requests that the effective date of the above-referenced registration statement be accelerated so that it will be declared effective at 9:00 a.m., Eastern Time, on August 22, 2025, or as soon thereafter as is practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes Alston & Bird LLP, counsel to the Registrant, to orally modify or withdraw this request for acceleration.

 The Registrant requests that it be notified of such effectiveness by a telephone call to Matthew Mamak of Alston & Bird LLP at (212) 210-1256.

 Thank you for your assistance in this matter. Should you have any questions, please call Mr. Mamak.

 Very truly yours,

 /s/ Rick Pauls

 Rick Pauls

 President and Chief Executive Officer